Tandem Diabetes Care Q1 net loss narrows

Tandem Diabetes Care

07/05/2026 22:02

Overview

U.S. insulin pump maker's Q1 revenue rose 5% yr/yr to $247 mln

Gross margin improved to 55% from 51% a year earlier

Net loss narrowed to $20.4 mln from $130.6 mln last year

Outlook

Tandem Diabetes Care sees 2026 sales at $1.065 bln to $1.085 bln

Company expects 2026 U.S. sales of $730 mln to $745 mln and international sales of $335 mln to $340 mln

Tandem Diabetes Care forecasts 2026 gross margin of 56% to 57% and adjusted EBITDA margin of 5% to 6%

Result Drivers

PUMP SHIPMENTS - Record first-quarter pump shipments, including 19,000 in the United States, contributed to higher sales

GROSS MARGIN IMPROVEMENT - Gross margin rose to 55%, up 480 basis points from a year earlier, driven by operational initiatives

NEW REIMBURSEMENT MODEL - Launched pay-as-you-go reimbursement model in the U.S. pharmacy channel, supporting sales growth

Company press release: ID:nBw24KyyWa

Key Details

Metric
Beat/Miss
Actual
Consensus Estimate
Q1 Net Income
-$20.39 mln
Q1 Gross Margin
55.00%
Q1 Operating income
-$17.43 mln


Analyst Coverage

The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 12 "strong buy" or "buy", 11 "hold" and no "sell" or "strong sell"

The average consensus recommendation for the medical equipment, supplies & distribution peer group is "buy"

Wall Street's median 12-month price target for Tandem Diabetes Care Inc is $29.00, about 60.8% above its May 6 closing price of $18.03

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)